Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Topical Cyclosporine and Disease Progression

This study has been completed.
Information provided by:
Innovative Medical Identifier:
First received: December 3, 2007
Last updated: September 23, 2008
Last verified: September 2008
The purpose of this study is to evaluate the effect Restasis has in regards to disease progression.

Condition Intervention Phase
Disease Progression
Disease Severity
Drug: Restasis
Drug: Endura
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Topical Cyclosporine and Disease Progression

Resource links provided by NLM:

Further study details as provided by Innovative Medical:

Primary Outcome Measures:
  • Disease Severity [ Time Frame: 1 yr ]

Secondary Outcome Measures:
  • Staining [ Time Frame: 1 yr ]

Estimated Enrollment: 80
Study Start Date: December 2007
Study Completion Date: September 2008
Primary Completion Date: September 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1. Drug: Restasis
Restasis- (in the eye) Instill one drop twice daily Endura- (in the eye) Instill one drop twice daily
Placebo Comparator: 2. Drug: Endura
Restasis- (in the eye) Instill one drop twice daily Endura- (in the eye) Instill one drop twice daily


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Mild to Moderate dry eye symptoms

Exclusion Criteria:

  • Current use of Restasis
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00567983

United States, Illinois
Lakeside Eye Clinic
Chicago, Illinois, United States, 60641
Sponsors and Collaborators
Innovative Medical
Principal Investigator: Sanjay Rao Lakeside Eye Clinic
  More Information

Responsible Party: Sanjay Rao, MD, Lakeside Eye Clinic Identifier: NCT00567983     History of Changes
Other Study ID Numbers: 13717A
Study First Received: December 3, 2007
Last Updated: September 23, 2008

Additional relevant MeSH terms:
Disease Progression
Disease Attributes
Pathologic Processes
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antifungal Agents
Anti-Infective Agents
Dermatologic Agents
Antirheumatic Agents
Calcineurin Inhibitors processed this record on May 25, 2017